Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Studies Point to Many Benefits of Weightbearing CT Scanning Technology

For patients whose lives are impacted by medical technology breakthroughs, there is a significant improvement in the quality of care their doctors are then able to provide. This is especially true when it comes to cone beam computed tomography (CT) scanning. In the last decade, the innovations made in this field have allowed for true…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

For patients whose lives are impacted by medical technology breakthroughs, there is a significant improvement in the quality of care their doctors are then able to provide. This is especially true when it comes to cone beam computed tomography (CT) scanning. In the last decade, the innovations made in this field have allowed for true weightbearing CT scans to be taken.

In order to present a picture of the difference weightbearing CT scanning has made on foot and ankle patients, authors from the University of Utah, as well as a team of international researchers, presented a series of studies showing the benefits of the new technology. In their article, Weightbearing Computed Topography of the Foot and Ankle: Emerging Technology Topical ReviewDrs. Alexej Barg and Charles Saltzman show that true weightbearing CT scans are far more effective than their simulated counterparts.

The article covered 8 studies performed between 2013 and 2017, each of which covered alignment analysis within the foot. While previous attempts to replicate weightbearing environments involved rigging up weights to affect the foot while the patient was lying down, modern technology is allowing doctors to observe the interactions within the foot in actual weightbearing scenarios with the patient standing and even walking. Regardless of whether the studies focused on talar anatomy, hindfoot alignment, valgus deformities or flat-footedness, the studies all had a similar theme. The cone beam weightbearing CT scan offered a more complete view of the relationships in the foot than what was attainable with traditional radiography.

Perhaps most importantly, the overview of the literature available pointed to several key benefits offered by this scanning technology. Not only does it allow for scans to be taken while the patient is standing, but there is increased spatial resolution and faster imaging times due to cone beam scanning. Plus, the side benefits of having lower radiation than traditional CT scans coupled with modest costs can help alleviate many patient concerns. The authors also advocate for utilizing the images provided through weightbearing CT scanning to establish standardized forefoot, midfoot and hindfoot alignment positions using anatomical landmarks, which could greatly enhance both diagnoses and care plan development for the patient.

Leading the charge in this innovative technology is CurveBeam. With a line of cone beam scanning devices like the InReach, LineUP and their standard PedCAT, CurveBeam allows clinics to offer weight bearing CT scanning to their patients to improve their quality of care. To learn more about the possibilities offered by devices like the PedCAT, or to see their products for yourself, visit http://www.curvebeam.com/products/pedcat/ today!

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512